By contrast, in a phase II trial of dabrafenib (a BRAF inhibitor) plus trametinib in BRAF V600-mutant CCA patients showed promising activity with low toxicity (ORR: 47%; mPFS: 7.2 months; mOS: 11.3 months) (Table 3) [82]. Here, BRAF is linked to cholangiocarcinoma.